Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Covington
Daiichi Sankyo
Harvard Business School
Medtronic
Cipla
Chinese Patent Office
QuintilesIMS
Express Scripts

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,458,374

« Back to Dashboard

Summary for Patent: 7,458,374
Title:Method and apparatus for vaporizing a compound
Abstract: Disclosed is a method and device for rapid heating of a coated substance which preferably includes a drug to vaporized for inhalation therapy. A device in accordance with the present invention preferably includes a substrate which has an interior surface surrounding an interior region and an exterior surface upon which the coated substance is to be adhered. Though the substrate is preferably metallic, it does not need to be. A combustible element is placed in the interior region of the rigid substrate and an igniter is connected to the combustible element. The igniter is for initiating oxidation of the combustible element. Preferably, the coated substance is vaporized inside of a housing to allow the vaporized drug to aerosolize and be inhaled by a user.
Inventor(s): Hale; Ron L. (Woodside, CA), Song; Soonho (Hillsborough, CA), Quintana; Reynaldo J. (Redwood City, CA), Zaffaroni; Alejandro C. (Atherton, CA), Rabinowitz; Joshua D. (Princeton, NJ)
Assignee: Alexza Pharmaceuticals, Inc. (Mountain View, CA)
Application Number:10/146,086
Patent Claim Types:
see list of patent claims
Composition; Device; Use;

Drugs Protected by US Patent 7,458,374

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Galen Uk ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,458,374

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,442,368 Delivery of stimulants through an inhalation route ➤ Try a Free Trial
7,063,830 Delivery of anti-migraine compounds through an inhalation route ➤ Try a Free Trial
7,987,846 Method and apparatus for vaporizing a compound ➤ Try a Free Trial
7,601,337 Delivery of antipsychotics through an inhalation route ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,458,374

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 365548 ➤ Try a Free Trial
Austria 401063 ➤ Try a Free Trial
Austria 401064 ➤ Try a Free Trial
Austria 404173 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
McKinsey
McKesson
US Department of Justice
Colorcon
Teva
Julphar
Queensland Health
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.